SSG
CLDX icon

Summit Securities Group’s Celldex Therapeutics CLDX Stock Holding History

Summit Securities Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1
Closed -$1K – 439
2013
Q2 		$1K Buy
+1
New +$197 ﹤0.01% 531

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Securities Group's CLDX Position: Q2 2026 in Review

Summit Securities Group opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 634 shares worth $23.6K. The stake represents ﹤0.01% of the portfolio and ranks #690 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in CLDX as recently as Q4 2025.

Summit Securities Group first reported a position in CLDX in Q2 2013 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Summit Securities Group held 634 shares of Celldex Therapeutics worth $23.6K as of Q2 2026.
  • Celldex Therapeutics was a new Summit Securities Group position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #690 holding.
  • Summit Securities Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.